Urinary proteomics for early diagnosis in diabetic nephropathy

Diabetes

Volumn 61, Issue 12, 2012, Pages 3304-3313

  Zürbig, Petra ^a   Jerums, George ^b   Hovind, Peter ^c   MacIsaac, Richard J ^d   Mischak, Harald ^a,e   Nielsen, Stine E ^c   Panagiotopoulos, Sianna ^b   Persson, Frederik ^c   Rossing, Peter ^c  

^a MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^b AUSTIN HEALTH   (Australia)

^c STENO DIABETES CENTER   (Denmark)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ARTICLE; CAPILLARY ELECTROPHORESIS; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; DIABETIC NEPHROPATHY; DISEASE MARKER; EARLY DIAGNOSIS; FEMALE; FOLLOW UP; HUMAN; LONGITUDINAL STUDY; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PREDICTION; PRIORITY JOURNAL; PROTEOMICS; URINALYSIS; URINARY PROTEOMICS;

ALBUMINURIA; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; ELECTROPHORESIS, CAPILLARY; HUMANS; MASS SPECTROMETRY; PROTEOMICS;

EID: 84870328390     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db12-0348     Document Type: Article

References (51)

1. Alebiosu CO, Ayodele OE. The global burden of chronic kidney disease and the way forward. Ethn Dis 2005;15:418-423 (Pubitemid 41245551)
2. Levey AS, Atkins RC, Coresh J, et al. Chronic kidney disease as a global public health problem: approaches and initiatives - a position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007;72:247-259 (Pubitemid 47172384)
3. Remuzzi G, Macia M, Ruggenenti P. Prevention and treatment of diabetic renal disease in type 2 diabetes: the BENEDICT study. J Am Soc Nephrol 2006;17(Suppl. 2):S90-S97
4. Levey AS, Eckardt KU, Tsukamoto Y, et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005;67:2089-2100 (Pubitemid 41623371)
5. Miller WG, Bruns DE, Hortin GL, et al.; National Kidney Disease Education Program-IFCC Working Group on Standardization of Albumin in Urine. Current issues in measurement and reporting of urinary albumin excretion. Clin Chem 2009;55:24-38
6. Parving HH, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy and neuropathy in patients with insulin dependent diabetes. Br Med J (Clin Res Ed) 1988;296:156-160
7. Mogensen CE. Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 1984;310:356-360 (Pubitemid 14179541)
8. Rossing P. Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005. Diabetologia 2006;49:11-19 (Pubitemid 43151607)
9. Caramori ML, Fioretto P, Mauer M. The need for early predictors of diabetic nephropathy risk: is albumin excretion rate sufficient? Diabetes 2000;49:1399-1408
10. Macisaac RJ, Jerums G. Diabetic kidney disease with and without albuminuria. Curr Opin Nephrol Hypertens 2011;20:246-257
11. Hovind P, Tarnow L, Rossing P, et al. Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study. BMJ 2004;328:1105
12. Perkins BA, Ficociello LH, Roshan B, Warram JH, Krolewski AS. In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010;77:57-64
13. Brenner BM, Cooper ME, de Zeeuw D, et al.; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-869
14. Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 2010;26:150-171
15. Jerums G, Premaratne E, Panagiotopoulos S, Clarke S, Power DA, MacIsaac RJ. New and old markers of progression of diabetic nephropathy. Diabetes Res Clin Pract 2008;82(Suppl. 1):S30-S37
16. Steinke JM. The natural progression of kidney injury in young type 1 diabetic patients. Curr Diab Rep 2009;9:473-479
17. Fliser D, Novak J, Thongboonkerd V, et al. Advances in urinary proteome analysis and biomarker discovery. J Am Soc Nephrol 2007;18:1057-1071 (Pubitemid 46536892)
18. Mischak H, Coon JJ, Novak J, Weissinger EM, Schanstra JP, Dominiczak AF. Capillary electrophoresis-mass spectrometry as a powerful tool in biomarker discovery and clinical diagnosis: an update of recent developments. Mass Spectrom Rev 2009;28:703-724
19. Mischak H, Delles C, Klein J, Schanstra JP. Urinary proteomics based on capillary electrophoresis-coupled mass spectrometry in kidney disease: discovery and validation of biomarkers, and clinical application. Adv Chronic Kidney Dis 2010;17:493-506
20. Decramer S, Wittke S, Mischak H, et al. Predicting the clinical outcome of congenital unilateral ureteropelvic junction obstruction in newborn by urinary proteome analysis. Nat Med 2006;12:398-400
21. Julian BA, Wittke S, Novak J, et al. Electrophoretic methods for analysis of urinary polypeptides in IgA-associated renal diseases. Electrophoresis 2007;28:4469-4483 (Pubitemid 350259049)
22. Haubitz M, Good DM, Woywodt A, et al. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in anti-neutrophil cytoplasmic antibody-associated vasculitis. Mol Cell Proteomics 2009;8:2296-2307
23. Kistler AD, Mischak H, Poster D, Dakna M, Wüthrich RP, Serra AL. Identification of a unique urinary biomarker profile in patients with autosomal dominant polycystic kidney disease. Kidney Int 2009;76:89-96
24. Rossing K, Mischak H, Dakna M, et al.; PREDICTIONS Network. Urinary proteomics in diabetes and CKD. J Am Soc Nephrol 2008;19:1283-1290
25. Alkhalaf A, Zürbig P, Bakker SJ, et al.; PREDICTIONS Group. Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS ONE 2010;5:e13421
26. Good DM, Zürbig P, Argilés A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010;9:2424-2437
27. Siwy J, Mullen W, Golovko I, Franke J, Zürbig P. Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin Appl 2011;5:367-374
28. Andersen S, Mischak H, Zürbig P, Parving HH, Rossing P. Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria. BMC Nephrol 2010;11:29
29. Zürbig P, Renfrow MB, Schiffer E, et al. Biomarker discovery by CE-MS enables sequence analysis via MS/MS with platform-independent separation. Electrophoresis 2006;27:2111-2125 (Pubitemid 43942113)
30. Kolch W, Neusüss C, Pelzing M, Mischak H. Capillary electrophoresis-mass spectrometry as a powerful tool in clinical diagnosis and biomarker discovery. Mass Spectrom Rev 2005;24:959-977 (Pubitemid 41641706)
31. Theodorescu D, Wittke S, Ross MM, et al. Discovery and validation of new protein biomarkers for urothelial cancer: a prospective analysis. Lancet Oncol 2006;7:230-240 (Pubitemid 43286453)
32. Neuhoff N, Kaiser T, Wittke S, et al. Mass spectrometry for the detection of differentially expressed proteins: a comparison of surface-enhanced laser desorption/ionization and capillary electrophoresis/mass spectrometry. Rapid Commun Mass Spectrom 2004;18:149-156 (Pubitemid 38160349)
33. Jantos-Siwy J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for biomarker evaluation in chronic kidney disease. J Proteome Res 2009;8:268-281
34. Coon JJ, Zürbig P, Dakna M, et al. CE-MS analysis of the human urinary proteome for biomarker discovery and disease diagnostics. Proteomics Clin Appl 2008;2:964-973
35. Girolami M, Mischak H, Krebs R. Analysis of complex, multidimensional datasets. Drug Discov Today Technol 2007;3:12-19
36. Yang ZR. Biological applications of support vector machines. Brief Bioinform 2004;5:328-338
37. Yang ZR, Chou KC. Bio-support vector machines for computational proteomics. Bioinformatics 2004;20:735-741 (Pubitemid 38443829)
38. Wittke S, Fliser D, Haubitz M, et al. Determination of peptides and proteins in human urine with capillary electrophoresis-mass spectrometry, a suitable tool for the establishment of new diagnostic markers. J Chromatogr A 2003;1013:173-181 (Pubitemid 37297584)
39. DeLeo JM. Receiver operating characteristic laboratory (ROCLAB): software for developing decision strategies that account for uncertainty. College Park, MD, Second International Symposium on Uncertainty Modeling and Analysis, 25 April 1993, p. 318-325
40. Mischak H, Kolch W, Aivaliotis M, et al. Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin Appl 2010;4:464-478
41. Mischak H, Rossing P. Proteomic biomarkers in diabetic nephropathy - reality or future promise? Nephrol Dial Transplant 2010;25:2843-2845
42. Haller H, Ito S, Izzo JL Jr, et al.; ROADMAP Trial Investigators. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-917
43. Bilous R, Chaturvedi N, Sjølie AK, et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-20, W3-4
44. Cheng S, Pollock AS, Mahimkar R, Olson JL, Lovett DH. Matrix metalloproteinase 2 and basement membrane integrity: a unifying mechanism for progressive renal injury. FASEB J 2006;20:1898-1900
45. Rossing K, Mischak H, Rossing P, Schanstra JP, Wiseman A, Maahs DM. The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy. Proteomics Clin Appl 2008;2:997-1007
46. Good DM, Thongboonkerd V, Novak J, et al. Body fluid proteomics for biomarker discovery: lessons from the past hold the key to success in the future. J Proteome Res 2007;6:4549-4555
47. Chakraborty J, Below AA, Solaiman D. Tamm-Horsfall protein in patients with kidney damage and diabetes. Urol Res 2004;32:79-83 (Pubitemid 38915394)
48. Sejdiu I, Torffvit O. Decreased urinary concentration of Tamm-Horsfall protein is associated with development of renal failure and cardiovascular death within 20 years in type 1 but not in type 2 diabetic patients. Scand J Urol Nephrol 2008;42:168-174 (Pubitemid 351451008)
49. Aronis KN, Kim YB, Mantzoros CS. Clusterin (apolipoprotein J): wither link with diabetes and cardiometabolic risk? Metabolism 2011;60:747-748
50. Ghiggeri GM, Bruschi M, Candiano G, et al. Depletion of clusterin in renal diseases causing nephrotic syndrome. Kidney Int 2002;62:2184-2194 (Pubitemid 35366174)
51. Hidaka S, Kränzlin B, Gretz N, Witzgall R. Urinary clusterin levels in the rat correlate with the severity of tubular damage and may help to differentiate between glomerular and tubular injuries. Cell Tissue Res 2002;310:289-296